• Accuri Cytometers (Ann Arbor, Michigan) reported the launch of CSampler, an optional accessory that adds simple, reliable and user-friendly automation to the Accuri C6 Flow Cytometer system, a revolutionary product designed to bring the power of flow cytometry analysis to the laboratory of every life science researcher. The Accuri CSampler is compatible with 48- and 96-well microplates and deep-well plates, and also comes with a 24-tube rack for standard 12x75mm test tubes. Users can run multiple experiments in a single plate and apply settings to specific wells or the entire plate, with the ability to construct templates. Accuri's polar-coordinates approach enables CSampler to move faster between distant wells than conventional automation systems, and its small, user-installable platform self-aligns.

• Entellus Medical (Minneapolis) reported the first enrollment in the FinESS Registry, a prospective, post-approval Registry study designed to assess subject rhinosinusitis symptomatic status of up to 500 patients treated with FinESS Sinus Treatment over time. The objective of the Registry is to assess subject rhinosinusitis symptomatic status at pre-treatment, six months and twelve months post-treatment following FinESS Sinus Treatment using data collected from validated, self-administered QoL (quality of life) surveys. FinESS Sinus Treatment is a less-invasive treatment option to break the cycle of chronic rhinosinusitis. It is for patients whose symptoms persist or return, despite antibiotics and steroids or for patients who do not need, want or can't have extensive sinus surgery.

• Evogen (Kansas City, Missouri) said it is developing multi-faceted capabilities to address the air-monitoring, detection and diagnosis of Influenza A H1N1, or Swine Flu, in addition to several prevalent flu types. Evogen's molecular PCR diagnostic test is capable of rapidly and specifically detecting H1N1 pandemic Influenza, using HyBeacons technology. The test can be implemented on PCR equipment currently used in laboratories globally or can be operated on Evogen's EvoCycler HD12 – which provides high-definition PCR results in a simple-to-use molecular diagnostic system that can be implemented at the "front line" in this global pandemic.

• Illumina (San Diego) reported software advancements for its sequencing platform that enable real time analysis and provide a significant reduction in computing infrastructure requirements. These software improvements, in combination with the new Genome Analyzer, enable researchers to increase their sequencing output up to 65% relative to the Genome Analyzer. The Illumina Genome Analyzer offers a set of supported applications, including whole transcriptome profiling and discovery, epigenetic studies, whole genome resequencing, de novo sequencing, targeted resequencing, ChIP-sequencing, bi-sulfite sequencing (DNA methylation), small RNA, mRNA, tag profiling and metagenomics.

• InformMed (Peoria, Illinois) reported the release of its evidenced-based decision support system designed to assure point-of-care medication safety and to assist in eliminating harmful medication errors. Based on the pac2 system, the solution called ally is designed to empower nurses as the last line of defense in the medication delivery process. ally backs front line nurses when and where they need accurate dosing and medication information. "Providing solutions that can help our hospital partners deliver safer healthcare to their communities is our single minded focus at InformMed. The ally system not only expands the breadth of support for nurses at the bedside, but it also captures critical dose calculated volume information that is essential for a comprehensive EMR," said CEO Gary Conkright.